BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20210101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220301
DTEND;VALUE=DATE:20220304
DTSTAMP:20260516T003105
CREATED:20211118T125811Z
LAST-MODIFIED:20211118T125903Z
UID:32125-1646092800-1646351999@www.pharmajournalist.com
SUMMARY:4th Chronic Kidney Disease Drug Development Summit
DESCRIPTION:As SGLT2 inhibitors redefine standard of care\, opportunities to establish efficacy with surrogate endpoints take a step forward\, and molecular phenotyping of disease etiology enables reclassification of patients to clinically actionable subtypes; drug development for chronic kidney disease has never been more exciting. \nThe 4th Chronic Kidney Disease Drug Development Summit is your only industry-led event dedicated to accelerating the frontier of preventative and regenerative therapies to meaningfully target kidney disease and enlighten opportunities for indication expansion into rare renal disorders. Uniting 100+ industry heavyweights including AstraZeneca\, Johnson & Johnson\, Bayer\, Boehringer Ingelheim\, Novartis\, Otsuka\, Novo Nordisk\, and many more\, this is a conversation you cannot afford to miss. \nFrom dissecting pivotal insight into implementing patient stratification to turn the tide on precision medicine\, to the brand-new seminar dedicated to establishing a pathway to clinical success in AKI\, this is the only end-to-end forum presenting scientific advancements as actionable insights. \nWe hope to see you in Boston this March to together discover opportunities to personalize organ-on-a-chip technology and explore advances in stem cell platforms to regenerate kidney tissue. Leave this meeting equipped to guide your strategic decisions for 2022 and implement evolving surrogate endpoints of eGFR slope\, albuminuria\, and real-world evidence into innovative trial design. \nTake a look at the event guide here.
URL:https://www.pharmajournalist.com/event/4th-chronic-kidney-disease-drug-development-summit/
LOCATION:Hyatt Regency Boston\, One Ave. de Lafayette\, Boston\, MA\, 02111\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220308
DTEND;VALUE=DATE:20220311
DTSTAMP:20260516T003105
CREATED:20211214T011809Z
LAST-MODIFIED:20211214T011809Z
UID:32510-1646697600-1646956799@www.pharmajournalist.com
SUMMARY:Transcription Factor-Directed Therapies Summit
DESCRIPTION:The FDA’s recent approval of Welireg has sparked reinvigorated confidence in the field of Transcription Factor-therapeutics and as an increasing number of drug candidates are entering preclinical and clinical programs\, this is a vital moment for the field. \nFor the first time\, you can join leaders from BMS\, Scorpion Therapeutics\, Ikena Oncology\, Kronos Bio and Talus Bio at the inaugural Transcription Factor-Directed Therapies Summit\, the first in-person conference on precision molecular oncology uniting experts in proteomics\, genomics\, structural biology\, and translational sciences. \nDedicated to overcoming specific drug development challenges of targeting this ubiquitous and highly complex system with novel TPD based modalities\, this unique discussion forum will equip you with the knowledge to utilize Transcription Factors as biomarkers to better predict disease prognosis and progression. \nDon’t miss your chance to join fellow pioneers of Transcription Factor medicine to overcome the critical roadblocks to success in small molecule inhibitors\, PROTAC-based degraders\, and other therapeutic approaches targeting STAT3\, c-MYC\, FOXP3\, p53\, MITF\, NF-B\, and many more Transcription Factors. \nEnsure your Transcription Factor program reaches full clinical potential by gaining a better understanding of the underpinning biology of the transcription regulation network and how it relates to treating disease\, whilst harnessing the novel discovery and screening technologies that are streamlining drug development and opening the field up to new therapeutics possibilities. Join us to seek out solutions to longstanding obstacles in transcription factor therapy development at all stages\, from bench to bedside. \nTo know more visit: https://bit.ly/3pWWEj8
URL:https://www.pharmajournalist.com/event/transcription-factor-directed-therapies-summit/
LOCATION:Hyatt Regency Boston\, One Ave. de Lafayette\, Boston\, MA\, 02111\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220314
DTEND;VALUE=DATE:20220316
DTSTAMP:20260516T003105
CREATED:20211220T170251Z
LAST-MODIFIED:20211220T170251Z
UID:32612-1647216000-1647388799@www.pharmajournalist.com
SUMMARY:SMi’s 3rd Annual AI in Drug Discovery Conference
DESCRIPTION:SMi’s 3rd Annual AI in Drug Discovery Conference \nConference: 14 – 15 March 2022\nLondon\, UK\nWebsite: http://www.ai-indrugdiscovery.com/PJwl \nChaired by Darren Green\, Director of Computational Chemistry\, GSK \nSponsored by: Optibrium \nExploring the Impact of Machine Learning and Artificial Intelligence in Drug Development from Discovery to Healthcare \nSMi Group is proud to present its 3rd Annual AI in Drug Discovery Conference\, taking place on the 14th and 15th March 2022 in London\, UK. \nWith the recent pandemic highlighting the need for rapid drug discovery\, AI has become an area of increased interest. This is driven by the ability to discover drugs through the use of machine and deep learning. The current challenges within the drug discovery industry include the significant time consumption and expenses involved. This conference will discuss the solutions to these problems with presentations and updates from leading industry experts. \nAI in drug discovery is leading the way into a shorter\, cheaper and more successful R&D era where compound generation is automated\, drug synthesis is predictable and undruggable diseases are finally being targeted. \nAI in drug discovery is becoming an integral part of the research and development area of treating diseases with more companies incorporating ‘Big Data’ and data scientists within their R&D teams. Although the AI in drug discovery area has grown rapidly over the past few years\, those in the industry acknowledge that there is a long way to go. Collaboration and partnerships are the key to driving this area forward. \nJoin us at SMi’s 3rd annual AI in Drug Discovery conference and explore the latest industry updates in: the selection of targets using AI\, decision making within drug discovery and closing the loop on AI in drug discovery. Don’t miss out on presentations from leaders within the field\, giving insights into the latest industry advances and answering the big questions within AI in Drug Discovery. \nEvent Hashtag: #SMiAIDrugDis \nKey Reasons to Attend: \n\nDiscover the main topics of research within industry\, with talks on decision making\, target selection and closing the loop\nEngage with regulators about the guidance within machine learning and AI in Drug Discovery\nLearn about the new breakthroughs within clinical trials and the treatment of disease\nExplore the latest technologies in deep learning from leaders within the pharmaceutical industry\nDiscuss the impact of big data and how it applies to AI drug discovery within Pharma\n\nWho Should Attend? \nCEOs\, Presidents\, Vice Presidents and Global Heads\, Executive Directors\, Vice President & Global head\, Principal Scientists\, Heads of Business Development\, Directors of Pharma/Biotech firms.
URL:https://www.pharmajournalist.com/event/smis-3rd-annual-ai-in-drug-discovery-conference/
LOCATION:London\, United Kingdom
ORGANIZER;CN="SMi Events":MAILTO:ssapal@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220315
DTEND;VALUE=DATE:20220318
DTSTAMP:20260516T003105
CREATED:20211122T103557Z
LAST-MODIFIED:20211227T114657Z
UID:32201-1647302400-1647561599@www.pharmajournalist.com
SUMMARY:2nd TPD Europe Summit
DESCRIPTION:2021 marked a successful year for the protein degradation field with several candidates entering the clinic. As the European centric targeted protein degradation landscape matures and the number of pre-clinical candidates expected to enter clinical development in the next year grows ever more\, the 2nd TPD Europe Summit returns\, in person\, to highlight key challenges and opportunities ahead! \nBuilt with biopharma in mind\, join us as we take a deep dive into how European leaders of protein degradation are approaching key translational challenges including optimisation of selectivity\, bioavailability and PKPD to ensure the safety\, efficacy and potency of their clinical pipelines in 2022 and beyond! \nBe at the heart of the discussion by joining 180+ Senior Scientists\, Principal Investigators & Heads of Discovery\, Pre-Clinical & Translational Development from Europe and around the globe for two dedicated streams of exciting content over three days to capitalise on this emerging therapeutic class. \nKey Highlights Not to Miss: \n\nHear from Kevin Moreau\, Assoicate Director PROTAC Safety Science\, AstraZeneca as he discusses key PROTAC safety considerations for both oncology and non-oncology indications including how to optimise the safety profile\, and what is acceptable for non-oncology targets\n\n\nDelve into COFFEE (covalent functionalisation followed by E3 electroporation)\, which tests neo-substrate degradation by chemically modified E3 ligase components. Brought to you by Benika Pinch\, Principal Scientist\, Novartis\, she discusses how to assess the cellular activity of E3 ligase components\n\n\nUncover how protein manipulation using peptides can be used to degrade proteins using either the UPS or lysosomal pathways. This exciting approach relocates protein within the cell and modulates their interactions. Hear Max Cynader\, CEO & Co-Founder Primary Peptides discuss in detail!\n\n\nAmine Sadok\, Head of Biology at Monte Rosa Therapeutics will be discussing how they have identified a potent and selective NEK7 molecular glue degrader as a novel CRBN neo-substrate\n\nDigital passes available \nTo know more visit: https://ter.li/j3ytqu
URL:https://www.pharmajournalist.com/event/2nd-tpd-europe-summit/
LOCATION:London\, UK
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220321
DTEND;VALUE=DATE:20220323
DTSTAMP:20260516T003105
CREATED:20211125T120837Z
LAST-MODIFIED:20211125T133706Z
UID:32219-1647820800-1647993599@www.pharmajournalist.com
SUMMARY:SMi Presents the 16th Annual Conference: Parallel Trade 2022
DESCRIPTION:SMi’s 16th Annual Conference\nParallel Trade\n21-22 March\, 2022 | Conference\nhttp://parallel-trade.com/pharmajournalistwl \nNAVIGATING THE CHALLENGES AND LEGAL LANDSCAPES OF PARALLEL TRADE \nSMi presents its 16th annual Parallel Trade conference on the 21st and the 22nd March 2022. As the only parallel trade conference in Europe\, this event provides the perfect platform for industry experts from both sides of the coin to come together and share perspectives on the practice of parallel trade. \nThe 2022 event will be more significant than ever before due to the transition period follow Brexit now also coming to an end. As such\, the UK will no longer be part of the EU free market. This will mean increased medicines prices\, reduced access to some specialist drugs and greater risk of supply chain shortages. In a post-Brexit environment\, exhaustion of rights will cease to apply to the UK\, making import and export a costly business and in a worst-case scenario could effectively kill parallel distribution. \nThis conference will bring together industry experts to discuss the challenges and drivers of the industry\, including the EU regulatory landscape and the impact of the Brexit and the Pandemic together. The conference will also provide global insights on Parallel trade and will reflect on key takeaways for other member states. \nBenefits of Attending: \n\nDiscover the impact of Covid-19 on Parallel trade as countries begin to release restrictions. How has the sector been influenced?\nEngage in discussions on the growth within parallel trade over the past year at the only Parallel Trade specific conference within the EU.\nDiscuss the impact on UK parallel trade following Brexit\, through the eyes of regulators\, the pharmaceutical industry and academics\nDevelop further understanding of the rules and regulation changes over the past 12 months\, Parallel Trade\, where are we now?\n\nWho Should Attend: \nVice President/ Heads of/General Managers:\n• International Trade and Relations\n• Supply Chain Development – Brexit\n• Brexit Implementation\n• Market Access\n• Supply Chain Manager\n• Parallel trade reporting\n• Regulatory Affairs\n• IP\n• Purchasing\n• Policy Patent Operations\n• European Affairs\n• Supply and Demand\n• Attorney\n• Distribution \nPlease visit http://parallel-trade.com/pharmajournalistwl for more information\, to download the full agenda\, or to register your place.  If you would like to speak to someone about the event please contact Alia Malick amalick@smi-online.co.uk or call +44 (0)20 7827 6168.
URL:https://www.pharmajournalist.com/event/smi-presents-the-16th-annual-conference-parallel-trade-2022/
LOCATION:Virtual Conference: Online Access Only
ORGANIZER;CN="Hanson Wade":MAILTO:rjones@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220322
DTEND;VALUE=DATE:20220325
DTSTAMP:20260516T003105
CREATED:20211111T123644Z
LAST-MODIFIED:20211111T123644Z
UID:32053-1647907200-1648166399@www.pharmajournalist.com
SUMMARY:GPCRs - Targeted Drug Discovery Summit
DESCRIPTION:The inaugural GPCRs – Targeted Drug Discovery Summit has been established to tap into new drug discovery opportunities in undrugged and orphaned GPCRs by better understanding the complex signaling GPCR pathway\, leveraging new structural and genetic data as well as\, emerging screening tools and technologies and up and coming modalities. \nDiscover data driven case studies that showcase the challenges\, learnings and takeaways currently being faced by large pharma\, biotech and academia who are innovating their discovery and development approaches to drug a wider spectrum of clinically relevant but poorly characterized or undrugged GPCRs across a broad range of therapeutic areas such as oncology\, age-related diseases and beyond. \nWhether you are looking to harness the power of structural biology tools or emerging technologies\, join fellow directors\, heads and VPs of drug discovery\, structural biology\, and pharmacology at the GPCRs – Targeted Drug Discovery Summit – the most comprehensive and dedicated scientific and networking forum for innovative biopharma and research institutes to seize the therapeutic opportunities of GPCRs. \nTo know more visit: https://ter.li/d9fxmw
URL:https://www.pharmajournalist.com/event/gpcrs-targeted-drug-discovery-summit/
LOCATION:DoubleTree Suites Boston-Cambridge\, 400 Soldiers Field Rd\, Boston\, MA\, 02134\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220322
DTEND;VALUE=DATE:20220325
DTSTAMP:20260516T003105
CREATED:20211214T012807Z
LAST-MODIFIED:20220124T113103Z
UID:32513-1647907200-1648166399@www.pharmajournalist.com
SUMMARY:STING & TLR-Targeting Therapies
DESCRIPTION:The 3rd STING & TLR-Targeting Therapies Summit is coming at a timely inflection point in this field. \nWith multiple TLR agonists moving into the clinic\, STING agonists exposing new challenges\, multiple approvals on the horizon\, and more novel targets & combinations currently undergoing exciting pre-clinical validation than ever before\, this unique and highly anticipated industry-focused meeting will unite experts in innate immunity to overcome the barriers it faces and accelerate clinical breakthrough. \nReturning in-person to the biopharma hub of Boston\, 30+ expert speakers will take you through case-study led presentations\, juicy panel discussions and live Q&A’s\, all tailored to suit your TLR\, STING & other PRR targeting needs. \nGain connections and insights to plan how to optimize the development of your innate immune agonists into the clinic and overcome obstacles that may impede the delivery of more selective\, better-tolerated medicines to improve survival rates in difficult-to-treat cancers. \nTo know more visit: https://ter.li/z3s9wq
URL:https://www.pharmajournalist.com/event/sting-tlr-targeting-therapies/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220329
DTEND;VALUE=DATE:20220401
DTSTAMP:20260516T003105
CREATED:20211130T161037Z
LAST-MODIFIED:20211130T161037Z
UID:32293-1648512000-1648771199@www.pharmajournalist.com
SUMMARY:3rd Annual Gene Therapy for Blood Disorders
DESCRIPTION:In the context of intense scrutiny over the safety and durability of blood disease-targeted gene therapies and a flurry of excitement around novel gene editing technologies\, the 3rd Gene Therapy for Blood Disorders Summit will unite the leading large pharma and innovative biotechs to share essential learnings from across this rapidly evolving field\, enabling you to progress your pipeline to address the significant unmet need in this field. \nFocused specifically on hemophilia\, beta-thallasemia and sickle cell-directed gene therapies and gene editing approaches\, this event is an invaluable opportunity to learn the realities of durability challenges\, understand strategies to guarantee safety at every stage of development and get a head-start in understanding the most promising technologies set to revolutionise the field. \nIncorporating insights from translational\, clinical and commercial industry experts\, as well as leading clinicians actively involved in late-stage trials\, this is your opportunity to investigate the realities of managing immunogenicity for systemically administered gene therapies\, establishing less cytotoxic conditioning regimens for ex vivo approaches and prepare for the commercial reality of launching a gene therapy and ensuring there is widespread patient adoption. \nTo know more visit: https://ter.li/u41qa2
URL:https://www.pharmajournalist.com/event/3rd-annual-gene-therapy-for-blood-disorders/
LOCATION:Boston Logan Airport Hotel\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220329
DTEND;VALUE=DATE:20220402
DTSTAMP:20260516T003105
CREATED:20211210T094616Z
LAST-MODIFIED:20211210T094922Z
UID:32479-1648512000-1648857599@www.pharmajournalist.com
SUMMARY:12th World ADC London
DESCRIPTION:12th Annual World ADC London\n29th March – 1st April 2022\nLondon \nThe ADC field is going from strength to strength\, further catalysed in 2021 by the approvals of Zynlonta and Tivdak respectively\, bringing the total number of commercially available ADCs to 11. \nReturning in-person in from 29th March – 1st April\, be part of the 12th Annual World ADC London and reconnect with 400+ of your peers at the forefront of ADC drug development. \nAfter in-depth research with key opinion leaders within the ADC field\, this is your most extensive programme to-date addressing the most pressing challenges facing ADC developers from discovery through to late phase manufacturing. \nTake a look at the brand-new agenda here! \nThe four-streamed\, four-day unrivalled programme with 75+ industry-leading speakers will equip you with the insights and connections to nourish your current pipelines of ADCs\, discover the next generation of non-traditional ADCs\, and confidently define your manufacturing processes. \nRegister now and join the likes of the likes of Daiichi Sankyo\, AstraZeneca\, ADC Therapeutics\, Seagen and many more to work collaboratively to overcome the distinct challenges ADC drug development holds and maximise the therapeutic window of ADCs.
URL:https://www.pharmajournalist.com/event/12th-world-adc-london/
LOCATION:Novotel London West\, 1 Shortlands\, Hammersmith\, London\, W6 8DR\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:adc@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220329
DTEND;VALUE=DATE:20220401
DTSTAMP:20260516T003105
CREATED:20220107T124627Z
LAST-MODIFIED:20220107T124627Z
UID:32748-1648512000-1648771199@www.pharmajournalist.com
SUMMARY:Next Generation Kinase Inhibitors Summit
DESCRIPTION:Celebrating 20 years of FDA approval and high efficacy profiles\, kinase inhibitors have changed the face of oncology treatment. However\, increasing resistance and safety issues limit the success of existing kinase inhibitor classes. \nThe inaugural Next Generation Kinase Inhibitors Summit is the only industry-focused meeting dedicated to applying novel kinase biology to drug development and innovating existing programs to produce the next wave of kinase inhibitor drugs which are able to show efficacious and durable clinical response in oncology and beyond. \nBoasting 20+ speakers\, 1 deep-dive workshop and over 3 days of unrivalled content spanning discovery\, R&D and clinical development\, this event is a unique opportunity for your team to identify and target the undruggable\, elevate drug design for improved target selectivity\, overcome the blood brain barrier and rationalize combinations for more durable responses. \nCollaborate with 80+ senior drug developers in March to achieve the next generation of these kinase inhibitor therapies with optimized specificity\, maximal durability to deliver the best clinical outcomes. \nTo know more visit: https://kinase-inhibitors-summit.com/
URL:https://www.pharmajournalist.com/event/next-generation-kinase-inhibitors-summit/
LOCATION:Boston Park Plaza\, 50 Park Plaza\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220330
DTEND;VALUE=DATE:20220402
DTSTAMP:20260516T003105
CREATED:20220211T093912Z
LAST-MODIFIED:20220211T094005Z
UID:33197-1648598400-1648857599@www.pharmajournalist.com
SUMMARY:7th Innate Killer Summit 2022
DESCRIPTION:2021 was a game-changing year for the NK cell community. Positive clinical results have forced the field to wake up to the potential of these pioneering approaches. \nSupporting the field since its’ infancy\, the Innate Killer Summit returns for its 7th year as the leading\, industry-defining forum dedicated to advancing the field to achieve clinical success. \nSpanning the current drug development landscape\, from improving gene editing transduction in discovery to cryopreservation and CMC in scaled manufacturing\, this is the definitive meeting to focus on the clinical and scaled phase development of innate cell therapies. \nGet your copy of the 2022 agenda here. \nJoin over 200 experts to characterize and contrast cell sources\, supercharge combinations\, optimize CMC workflows\, examine expansion protocols for high-quality products at scale\, and move the field towards persistent\, scalable\, and cost-effective innate immune cell therapies. \nPromising unpublished data\, interactive discussion\, and engaging networking opportunities join this exclusive summit to forge new collaborations and capitalize on the clinical potential of innate immune cell therapies.
URL:https://www.pharmajournalist.com/event/7th-innate-killer-summit-2022/
LOCATION:Sheraton San Diego Hotel & Marina\, 1380 Harbor Island Drive\, San Diego\, CA\, 92101\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR